Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
Current Oncology Reports · 2024-08 · 26 (8) · 890-903
DOI: 10.1007/s11912-024-01560-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology Reports, online erschienen am 01.06.2024. Verfasst von Gordon R Daly und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland. gordondaly@rcsi.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Recombinational DNA Repair. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Now, Royal College of Surgeons in Ireland.
Abstract (Originalsprache)
Purpose of Review Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context. Recent Findings Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer. However, despite the improved affordability of next-generation sequencing (NGS) and the discovery of PARP inhibitors, economic and geographical barriers in access to HRD testing and breast cancer screening do not allow all patients to benefit from the personalized treatment approach they provide. Summary Advancements in HRD testing modalities and targeted therapeutics enable tailored breast cancer management. However, inequalities in access to testing and optimized treatments are contributing to widening health disparities globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland. gordondaly@rcsi.com.
- The Department of Surgery, Beaumont Hospital, Dublin, Ireland. gordondaly@rcsi.com.
- The Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- The Department of Surgery, Beaumont Hospital, Dublin, Ireland.
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.
Förderung
- Breast Cancer Now
- Royal College of Surgeons in Ireland
Zitieren
APA
Daly, G. R., Naidoo, S., Alabdulrahman, M., McGrath, J., Dowling, G. P., AlRawashdeh, M. M., Hill, A. D. K., Varešlija, D., & Young, L. (2024). Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape. Current Oncology Reports, 26(8), 890-903. https://doi.org/10.1007/s11912-024-01560-3
Vancouver
Daly GR, Naidoo S, Alabdulrahman M, McGrath J, Dowling GP, AlRawashdeh MM, et al. Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape. Current Oncology Reports. 2024;26(8):890-903. doi:10.1007/s11912-024-01560-3
BibTeX
@article{Daly2024,
author = {Daly, Gordon R and Naidoo, Sindhuja and Alabdulrahman, Mohammad and McGrath, Jason and Dowling, Gavin P and AlRawashdeh, Maen M and Hill, Arnold D K and Varešlija, Damir and Young, Leonie},
title = {Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape},
journal = {Current Oncology Reports},
year = {2024},
volume = {26},
number = {8},
pages = {890--903},
doi = {10.1007/s11912-024-01560-3}
}
EUVIMED